Biostem Technologies Stock Price To Sales
| BSEM Stock | USD 15.49 0.49 3.27% |
Biostem Technologies fundamentals help investors to digest information that contributes to Biostem Technologies' financial success or failures. It also enables traders to predict the movement of Biostem OTC Stock. The fundamental analysis module provides a way to measure Biostem Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostem Technologies otc stock.
Biostem |
Biostem Technologies OTC Stock Price To Sales Analysis
Biostem Technologies' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Biostem Technologies Price To Sales | 151.81 X |
Most of Biostem Technologies' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostem Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Biostem Technologies has a Price To Sales of 151 times. This is much higher than that of the Healthcare sector and 54.26% higher than that of the Biotechnology industry. The price to sales for all United States stocks is notably lower than that of the firm.
Biostem Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostem Technologies' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biostem Technologies could also be used in its relative valuation, which is a method of valuing Biostem Technologies by comparing valuation metrics of similar companies.Biostem Technologies is currently under evaluation in price to sales category among its peers.
Biostem Fundamentals
| Return On Equity | -2.21 | |||
| Return On Asset | -0.6 | |||
| Operating Margin | (18.22) % | |||
| Current Valuation | 37.89 M | |||
| Shares Outstanding | 9.24 M | |||
| Price To Earning | (0.49) X | |||
| Price To Sales | 151.81 X | |||
| Revenue | 2.52 M | |||
| Gross Profit | 163.78 K | |||
| EBITDA | (1.59 M) | |||
| Net Income | (2.39 M) | |||
| Cash And Equivalents | 1.37 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 1.32 M | |||
| Current Ratio | 0.26 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (581.57 K) | |||
| Earnings Per Share | (0.58) X | |||
| Target Price | 6.3 | |||
| Number Of Employees | 13 | |||
| Beta | 1.56 | |||
| Market Capitalization | 34.19 M | |||
| Total Asset | 2.67 M | |||
| Retained Earnings | (5.31 M) | |||
| Working Capital | (1.55 M) | |||
| Current Asset | 307 K | |||
| Current Liabilities | 1.86 M | |||
| Z Score | 13.6 | |||
| Net Asset | 2.67 M |
About Biostem Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostem Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostem Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostem Technologies based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.